SG2918

DRUG2 trials

Sponsors

Hangzhou Sumgen Biotech Co., Ltd.

Conditions

Advanced Malignant TumorsRelapsed/Refractory Multiple Myeloma

Phase 1

SG2918 For Advanced Malignant Tumors

CompletedNCT06167486

Hangzhou Sumgen Biotech Co., Ltd.Advanced Malignant Tumors

Start: 2023-12-26End: 2025-11-11Updated: 2026-09-04

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

RecruitingNCT07454187

Hangzhou Sumgen Biotech Co., Ltd.Relapsed/Refractory Multiple Myeloma

Start: 2026-04-16End: 2028-12-31Target: 40Updated: 2026-07-10